natgillin/translations-raw huggingface dataset:
Biotransformation: Studier på mennesker og in vitro-studier med brug af humane levermikrosomer har vist, at atazanavir hovedsagelig metaboliseres til oxygenerede metabolitter af CYP3A4-isozymer.
Metabolism: studies in humans and in vitro studies using human liver microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites.
Nedsat nyrefunktion: Hos raske forsøgspersoner var den renale udskillelse af uomdannet atazanavir cirka 7% af den administrerede dosis.
Renal impairment: in healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose.
Du må ikke åbne brevet, før det skal anvendes.
Do not open the sachet until ready to use.
Der findes en pakningsstørrelse: 1 æske med 30 breve.
One pack size is available: 1 carton with 30 sachets.
Hvis REYATAZ administreres sammen med parenteral midazolam, bør dette foregå på en intensivafdeling eller tilsvarende afdeling, som sikrer tæt klinisk monitorering og relevant behandling i tilfælde af respirationsdepression og/eller forlænget sedering.
If REYATAZ is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
b Ti patienter havde baseline fænotyperesistens over for atazanavir + ritonavir (foldændring [FC]>5,2).
b Ten patients had baseline phenotypic resistance to atazanavir + ritonavir (fold change [FC]>5.2).
1,3 g saccharose pr. brev.
1.3 g of sucrose per sachet.
- - Aktivt stof: atazanavir.
- The active substance is atazanavir.
Under forsøg på at kompensere for den nedsatte eksponering ved at øge dosis af REYATAZ, eller andre proteasehæmmere med ritonavir, er der set en høj frekvens af leverreaktioner.
During attempts to overcome the decreased exposure by increasing the dose of REYATAZ or other protease inhibitors with ritonavir, a high frequency of liver reactions was seen.
Det er muligt at dosis skal ændres i forbindelse med et skift fra oralt pulver til kapsler.
A change in dose may occur when switching between oral powder and capsules.
Hvis du har glemt at tage REYATAZ
If you forget to take REYATAZ
Diabetespatienter skal tage hensyn hertil.
This should be taken into account in patients with diabetes mellitus.
Tabel 5: Effektresultater i Studie 138a
Table 5: Efficacy Outcomes in Study 138 a
Hvis du holder op med at tage REYATAZ Du må ikke holde op med at tage REYATAZ uden at have talt med lægen.
If you stop taking REYATAZ Do not stop taking REYATAZ before talking to your doctor.
Atazanavir er en azapeptid hiv-1-proteasehæmmer (PI).
Atazanavir is an azapeptide HIV-1 protease inhibitor (PI).
Baseret på data fra andre boostede PI'er og ketoconazol, hvor ketoconazol-AUC viste en 3-fold stigning, forventes REYATAZ/ritonavir at øge ketoconazol- og itraconazolkoncentrationerne.
Based on data obtained with other boosted PIs and ketoconazole, where ketoconazole AUC showed a 3-fold increase, REYATAZ/ritonavir is expected to increase ketoconazole or itraconazole concentrations.
Høje doser ketoconazol og itraconazol (>200 mg/dag) frarådes.
High doses of ketoconazole and itraconazole (>200 mg/day) are not recommended.
REYATAZ en daglig dosis ritonavir en daglig dosis mindst 5 til under 15
REYATAZ once daily dose ritonavir once daily dose at least 5 to less than 15
Anden antiretroviral behandling end REYATAZ kan overvejes såfremt gulsot eller scleral icterus ikke er acceptabelt for patienten.
Alternative antiretroviral therapy to REYATAZ may be considered if jaundice or scleral icterus is unacceptable to a patient.
På baggrund af eksisterende virologiske og kliniske data for voksne patienter forventes der ikke gavnlig effekt hos patienter med stammer, der er resistente over for flere proteasehæmmere (≥ 4 PImutationer).
Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).
63 mg aspartam pr. brev.
63 mg of aspartame per sachet.
4.4 Seponering af ritonavir udelukkende under restriktive omstændigheder).
(See section 4.4 Withdrawal of ritonavir only under restrictive conditions).
d Ritonavir oral opløsning eller kapsler/tabletter.
d Ritonavir oral solution or capsule/tablet.
Opbevaringsforhold efter opblanding af lægemidlet, se pkt.
For storage conditions after mixing of the medicinal product, see section 6.3.
Hvis du glemmer en dosis eller glemmer at give dit barn en dosis, skal du tage eller give den manglende dosis så hurtigt som muligt sammen med et måltid, og derefter tage næste planlagte dosis til sædvanlig tid.
If you miss a dose or if you forget to give your child a dose, take or give the missed dose as soon as possible with food and then take or give the next scheduled dose at its regular time.
Under hiv-behandling kan der forekomme vægtstigning samt forhøjede niveauer af lipider og glucose i blodet.
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose.
Stoffet blokerer bearbejdningen af virale gagpol-proteiner i hiv-1 inficerede celler og hindrer dermed dannelsen af modne virioner og infektion af andre celler.
The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.
*Ritonavirkapsler, -tabletter eller oral opløsning kan anvendes.
*Ritonavir capsules, tablets or oral solution may be used.
Hvis patienten har udviklet SJS eller DRESS under behandling med REYATAZ, bør REYATAZ-behandling ikke genoptages.
If the patient has developed SJS or DRESS associated with the use of REYATAZ, REYATAZ may not be restarted.
Andelen af patienter med hiv-RNA < 400 kopier/ml var 53% og 43% for ATV/RTV og 54% og 46% for LPV/RTV ved henholdsvis uge 48 og 96.
The proportion of patients with HIV RNA < 400 copies/ml were 53% and 43% for ATV/RTV and 54% and 46% for LPV/RTV at weeks 48 and 96 respectively.
Anvendelse af REYATAZ til børn under 3 måneder og som vejer under 5 kg, er ikke blevet undersøgt på grund af risikoen for alvorlige komplikationer.
The use of REYATAZ in children less than 3 months of age and weighing less than 5 kg has not been studied due to the risk of serious complications.
almindelig: træthed ikke almindelig: brystsmerter, ubehag, pyreksi, asteni sjælden: gangforstyrrelser a Disse bivirkninger blev identificeret under post-marketing-overvågning, men hyppigheden er dog estimeret ud fra en statistisk beregning baseret på det totale antal patienter, der har været eksponeret for REYATAZ i randomiserede, kontrollerede og andre tilgængelige kliniske studier (n = 2.321).
common: fatigue; uncommon: chest pain, malaise, pyrexia, asthenia; rare: gait disturbance a These adverse reactions were identified through post-marketing surveillance, however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to REYATAZ in randomised controlled and other available clinical trials (n = 2321).
Det skal du vide, før du begynder at tage REYATAZ 3.
What you need to know before you take REYATAZ 3.
MINDSTEKRAV TIL MÆRKNING PÅ SMÅ INDRE EMBALLAGER REYATAZ 50 mg ORALT PULVER - FOLIEBREV 1.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS REYATAZ 50 mg ORAL POWDER - FOIL SACHET 1.
I et flerdosis-studie med hivinficerede patienter, der fik 400 mg atazanavir én gang dagligt med et let måltid i 12 uger, kunne atazanavir påvises i cerebrospinalvæsken og sæd.
In a multiple-dose study in HIVinfected patients dosed with 400 mg of atazanavir once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen.
Efter opblanding med føde eller drikke, kan blandingen opbevares i op til 1 time ved temperaturer under 30°C.
After mixing with food or beverage, mixture may be stored for up to 1 hour at temperatures not above 30°C.
Vurderingen af farmakokinetik, sikkerhed, tolerabilitet og virologisk respons for REYATAZ oralt pulver var baseret på data fra to åbne, multicenterundersøgelser.
Assessment of the pharmacokinetics, safety, tolerability, and virologic response of REYATAZ oral powder was based on data from two open-label, multicenter clinical trials.
Samtidig administration af REYATAZ med produkter indeholdende voxilaprevir forventes at øge koncentrationen af voxilaprevir.
Co-administration of REYATAZ with voxilaprevircontaining products is expected to increase the concentration of voxilaprevir.
Hvis du har taget for mange REYATAZ-kapsler Gulfarvning af huden/øjnene (gulsot) og uregelmæssig hjerterytme (QTc-forlængelse) kan forekomme, hvis du eller dit barn har taget for meget REYATAZ.
Yellowing of the skin and/or eyes (jaundice) and irregular heart beat (QTc prolongation) may occur if you or your child take too much REYATAZ.
Klip langs den stiplede linje.
Cut each sachet along the dotted line.
Tabel 6: Effektresultater ved uge 48a og uge 96 (Studie 045) Parameter
Table 6: Efficacy Outcomes at Week 48a and at Week 96 (Study 045) Parameter
Tabel 5: Effektresultater i Studie 138a Parameter
Table 5: Efficacy Outcomes in Study 138 a Parameter
REYATAZ + saquinavir er vist at være ringere end lopinavir + ritonavir.
REYATAZ + saquinavir was shown to be inferior to lopinavir + ritonavir.
Mødre med hiv-infektion frarådes at amme, da virus kan overføres gennem mælken.
It is recommended that women infected with HIV do not breast-feed because the virus might be transmitted through the breast milk.
Interaktioner mellem atazanavir og andre lægemidler angives i tabellen nedenfor (stigninger er angivet med “↑”, fald med “↓”, ingen ændring med “↔”).
Interactions between atazanavir and other medicinal products are listed in the table below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”).
Det er vigtigt at nævne, at mange studier er udført med ikke-boostet atazanavir, hvilket ikke er det godkendte atazanavir-regime.
Of importance, many studies were conducted with unboosted atazanavir, which is not the approved regimen of atazanavir.
Du må ikke tage eller give en dobbeltdosis som erstatning for den glemte dosis.
Do not take or give a double dose to make up for a forgotten dose.
Den øgede progestin-eksponering kan give bivirkninger (f.eks. insulinresistens, dyslipidæmi, akne og pletblødning), hvorved compliance muligvis påvirkes.
The increase in progestin exposure may lead to related side-effects (e.g. insulin resistance, dyslipidemia, acne and spotting), thus possibly affecting the compliance.
CD4 Middelændring fra baseline, celler/mm3 Alle patienter 110 (n=83) 122 (n=60) 121 (n=94) 154 (n=60)
CD4 Mean Change from Baseline, cells/mm3 All patients 110 (n=83) 122 (n=60) 121 (n=94) 154 (n=60)
4 forsøgspersoner i gruppen med ikke-boostet REYATAZ og 2 forsøgspersoner i gruppen med REYATAZ + ritonavir havde hivRNA > 500 kopier/ml i vedligeholdelsesfasen.
Four subjects in the unboosted REYATAZ group and 2 in the REYATAZ + ritonavir group had HIV RNA > 500 copies/ml during the maintenance phase.
Farmakokinetik for atazanavir er evalueret hos raske, voksne frivillige og hos hiv-inficerede patienter; der er observeret væsentlige forskelle mellem de to grupper.
The pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients; significant differences were observed between the two groups.
Post partuma (n=36)
postpartuma (n=36)
100 mgc aHvert brev indeholder 50 mg REYATAZ bRitonavir oral opløsning cRitonavir oral opløsning eller kapsler/tabletter
100 mgc aEach sachet contains 50 mg of REYATAZ bRitonavir oral solution cRitonavir oral solution or capsule/tablet
Tabel 8: Effektresultater for oralt pulver (pædiatriske patienter på mindst 3 måneder og som vejer mindst 5 kg) ved uge 48 (studierne AI424-397 og AI424-451) Parameter
Table 8: Efficacy Outcomes for oral powder (paediatric patients at least 3 months of age and weighing at least 5 kg) at Week 48 (Studies AI424-397 and AI424-451) Parameter
Vurdering af farmakokinetik, sikkerhed, tolerabilitet og virkning af REYATAZ er baseret på data fra et åbent, klinisk multicenterstudie (AI424-020), der blev udført med patienter i alderen 3 måneder til 21 år.
Assessment of the pharmacokinetics, safety, tolerability, and efficacy of REYATAZ is based on data from the open-label, multicenter clinical trial AI424-020 conducted in patients from 3 months to 21 years of age.
AI424-451 (PRINCE II): Hos pædiatriske patienter fra 3 måneder til under 11 år I disse studier fik 155 patienter (59 antiretroviral-naive og 96 antiretroviral-erfarne) en daglig dosis REYATAZ oralt pulver og ritonavir i kombination med to NRTI'er.
AI424-451 (PRINCE II): In paediatric patients from 3 months to less than 11 years of age In these studies, 155 patients (59 antiretroviral-naive and 96 antiretroviral-experienced) received once daily REYATAZ oral powder and ritonavir, in combination with two NRTIs.
Hvis oral kontraception administreres samtidig med REYATAZ/ritonavir, anbefales det, at det indeholder mindst 30 μg ethinylestradiol, og at patienten forstår nødvendigheden af omhyggelig compliance med dette kontraceptionsmiddel.
If an oral contraceptive is administered with REYATAZ/ritonavir, it is recommended that the oral contraceptive contain at least 30 μg of ethinyloestradiol and that the patient be reminded of strict compliance with this contraceptive dosing regimen.
Hyppigheden af behandlingsrelateret hepatitis eller transaminaseforhøjelser hos samtidigt inficerede patienter var sammenlignelig mellem REYATAZ og sammenlignelige regimer (se pkt.
The frequency of treatment emergent hepatitis or transaminase elevations in co-infected patients was comparable between REYATAZ and comparator regimens (see section 4.4).
Følgende anvisninger fortæller, hvordan du tilbereder og giver en dosis REYATAZ oralt pulver.
These instructions show you how to prepare and give a dose of REYATAZ oral powder.
Hos antiretroviralt behandlingserfarne patienter fra studie 009, 043 og 045 blev 100 isolater fra patienter angivet som virologisk svigt under behandling, der omfattede enten atazanavir, atazanavir + ritonavir eller atazanavir + saquinavir og blev fastsat til at have udviklet resistens over for atazanavir,.
Antiretroviral treatment experienced adult patients In antiretroviral treatment experienced patients from Studies 009, 043, and 045, 100 isolates from patients designated as virological failures on therapy that included either atazanavir, atazanavir + ritonavir, or atazanavir + saquinavir were determined to have developed resistance to atazanavir.
Fødepåvirkning: samtidig indtag af REYATAZ og ritonavir og mad optimerer biotilgængeligheden af atazanavir.
Food effect: co-administration of REYATAZ and ritonavir with food optimises the bioavailability of atazanavir.
Kontakt lægen eller apotekspersonalet, før du tager REYATAZ, og vær sikker på, at din læge ved det: hvis du har hepatitis B eller C hvis du får tegn eller symptomer på galdesten (smerter i højre side af maven) hvis du har type A- eller B-blødersygdom hvis du er i hæmodialysebehandling.
Talk to your doctor or pharmacist before taking REYATAZ and make sure your doctor knows: if you have hepatitis B or C if you develop signs or symptoms of gall stones (pain at the right side of your stomach) if you have type A or B haemophilia if you require haemodialysis
Effekt ved eksponering af atazanavir og ritonavir er ikke blevet undersøgt.
Effect on atazanavir and ritonavir exposure has not been studied.
Femten ud af 120 (13%) patienter i REYATAZ + ritonavir-behandlingsarmen og 17 ud af 123 (14%) patienter i lopinavir + ritonavir-armen havde fire eller flere af PI-substitutionerne L10, M46, I54, V82, I84 og L90.
Fifteen of 120 (13%) patients in the REYATAZ + ritonavir treatment arm and 17 of 123 (14%) patients in the lopinavir + ritonavir arm had four or more of the PI substitutions L10, M46, I54, V82, I84, and L90.
REYATAZ bør ikke anvendes til børn under 3 måneder på grund af problemstillinger vedrørende sikkerhed, især på grund af den potentielle risiko for kernicterus.
REYATAZ should not be used in children less than 3 months because of safety concerns especially taking into account the potential risk of kernicterus.
Ciclosporin Tacrolimus Sirolimus
Immunosuppressants Cyclosporin Tacrolimus Sirolimus
Tabel 7: Effektparametre (pædiatriske patienter fra 6 år til under 18 år) ved uge 48 (AI424-020 studie)
Table 7: Efficacy Outcomes (paediatric patients 6 years to less than 18 years of age) at Week 48 (Study AI424-020)
Der kan ikke gives anbefalinger vedrørende dosisreduktion; der bør derfor udvises forsigtighed, hvis REYATAZ administreres samtidig med clarithromycin.
No recommendation regarding dose reduction can be made; therefore, caution should be exercised if REYATAZ is coadministered with clarithromycin.
Sikkerhed og effekt af REYATAZ er ikke bestemt hos patienter med signifikante underliggende leverforstyrrelser.
The safety and efficacy of REYATAZ has not been established in patients with significant underlying liver disorders.
- - Øvrige indholdsstoffer: aspartam (E951), saccharose og Appelsin-vaniljesmagsstof.
- The other ingredients are aspartame (E951), sucrose and orange vanilla flavour.
Medicinen nedsætter mængden af hiv i kroppen og styrker derved immunforsvaret.
They work by reducing the amount of HIV in your body and this in turn, strengthens your immune system.
Tag REYATAZ sammen med mad (et måltid eller et større mellemmåltid).
Take REYATAZ capsules with food (a meal or a substantial snack).
M184I/V substitution opstod hos henholdsvis 5/26 REYATAZ/ritonavir og 7/26 lopinavir/ritonavir patienter med virologisk svigt.
The M184I/V substitution emerged in 5/26 REYATAZ/ritonavir and 7/26 lopinavir/ritonavir virologic failure patients, respectively.
REYATAZ oralt pulver indeholder:
REYATAZ oral powder contains :
Placer sprøjten i barnets mund ind mod kinden og tryk stemplet ned for at give medicinen.
Place the syringe in your child's mouth towards the cheek and push the plunger down to release the medicine.
Tilsæt yderligere 15 ml væske, rør rundt og få barnet til at drikke blandingen.
Add another 15 ml of the drink, mix and have the child drink the mixture.
Patienter med kronisk hepatitis B eller C, som er behandlet med antiretroviral kombinationsbehandling, har øget risiko for svære og potentielt dødelige leverbivirkninger.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Samtidig indtag af fedtrigt måltid påvirkede ikke AUC for atazanavir i forhold til i fastende tilstand, og Cmax lå inden for 11% i forhold til fasteværdierne.
Co-administration with a high-fat meal did not affect the AUC of atazanavir relative to fasting conditions and the Cmax was within 11% of fasting values.
Interaktionsmekanismen mellem REYATAZ/ritonavir og sofosbuvir/velpatasvir/voxilaprevir er hæmning af OATP1B, Pgp, og CYP3A.
The mechanism of interaction between REYATAZ/ritonavir and sofosbuvir/velpatasvir/voxilaprevir is inhibition of OATP1B, Pgp, and CYP3A.
Ritonavir kan reducere plasmakoncentrationen af phenytoin og/eller phenobarbital på grund af CYP2C9- og CYP2C19-induktion.
Ritonavir may decrease plasma levels of phenytoin and/or phenobarbital due to CYP2C9 and CYP2C19 induction.
Selvom det ikke er undersøgt, er der risiko for en øget pravastatin- eller fluvastatineksponering ved administration sammen med proteasehæmmere.
Although not studied, there is a potential for an increase in pravastatin or fluvastatin exposure when coadministered with protease inhibitors.
Linearitet/non-linearitet: Farmakokinetik for atazanavir er evalueret hos raske, voksne frivillige og hos hiv-inficerede patienter; der er observeret væsentlige forskelle mellem de to grupper.
Linearity/non-linearity: the pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV infected patients; significant differences were observed between the two groups.
Patienter, som fik REYATAZ eller REYATAZ/ritonavir på et vilkårligt tidspunkt før studieinklusion eller som havde behandlingssvigt i anamensen med to eller flere proteasehæmmere, proteasehæmmerresistens eller tegn på præeksisterende hjerteanomalier blev ekskluderet fra studierne.
Patients who received REYATAZ or REYATAZ/ritonavir at any time prior to study enrollment or who had a history of treatment failure on two or more protease inhibitors, protease inhibitor resistance or evidence of pre-existing cardiac abnormalities were excluded from the trials.
TEKST PÅ YDRE ÆSKE (BEHOLDER OG BLISTRE) OG TEKST PÅ ETIKET TIL BEHOLDER
OUTER CARTON TEXT (BOTTLE AND BLISTER PRESENTATIONS) AND BOTTLE LABEL TEXT
I denne periode skal post partum-patienter følge de samme dosisanbefalinger som ikke-gravide, inklusive anbefalingerne for samtidig administration af lægemidler, der er kendt for at påvirke atazanavireksponeringen (se pkt.
During this time, postpartum patients should follow the same dose recommendation as for nonpregnant patients, including those for co-administration of medicinal products known to affect atazanavir exposure (see section 4.5).
Enkeltdosis af famotidin bør aldrig overstige 20 mg, og den totale daglige dosis af famotidin bør ikke overstige 40 mg. at det er nødvendigt at tage højde for, at samtidig administration af voriconazol og REYATAZ uden ritonavir kan påvirke koncentrationen af atazanavir samtidig administration af fluticason og REYATAZ uden ritonavir kan øge koncentrationen af fluticason i forhold til administration af fluticason alene ved samtidig administration af et oralt kontraceptivum og REYATAZ uden ritonavir, anbefales det, at det orale kontraceptivum indeholder højst 30 µg ethinylestradiol dosisjustering af lamotrigin ikke er nødvendig
No single dose of famotidine should exceed 20 mg, and the total daily dose of famotidine should not exceed 40 mg. the need to consider that co-administration of voriconazole and REYATAZ without ritonavir may affect atazanavir concentrations co-administration of fluticasone and REYATAZ without ritonavir may increase fluticasone concentrations relative to fluticasone given alone if an oral contraceptive is administered with REYATAZ without ritonavir, it is recommended that the oral contraceptive contain no more than 30 µg of ethinyloestradiol no dose adjustment of lamotrigine is required
Polyesterfilm/aluminium/polyethylen brev med klæbelukning.
Polyester film/Aluminum/Polyethylene sealant film sachet.
Der foreligger ingen farmakokinetiske data for REYATAZ med ritonavir hos patienter med nyreinsufficiens.
There are no pharmacokinetic data available for REYATAZ with ritonavir in patients with renal insufficiency.
I toksicitetsstudier med gentagne doser på mus, rotter og hunde var atazanavirrelaterede fund generelt begrænset til leveren og omfattede generelt minimale til milde forhøjelser af serum bilirubin og leverenzymer, hepatocellulær vacuolation og hypertrofi, og kun i hunmus hepatisk enkeltcellenekrose.
In repeat-dose toxicity studies, conducted in mice, rats, and dogs, atazanavir-related findings were generally confined to the liver and included generally minimal to mild increases in serum bilirubin and liver enzymes, hepatocellular vacuolation and hypertrophy, and, in female mice only, hepatic singlecell necrosis.
Samtidig administration med REYATAZ/ritonavir kan potentielt reducere eller, mindre hyppigt, øge International Normaliseret Ratio (INR).
Co-administration with REYATAZ/ritonavir has the potential to produce a decrease or, less often, an increase in INR (International Normalised Ratio).
Totalt fik 182 pædiatriske patienter (81 antiretroviral-naive og 101 antiretroviral-erfarne) i dette studie REYATAZ en gang dagligt (kapsler eller pulverformulering) med eller uden ritonavir, i kombination med to NRTI'er.
Overall in this study, 182 paediatric patients (81 antiretroviral-naive and 101 antiretroviral-experienced) received once daily REYATAZ (capsule or powder formulation), with or without ritonavir, in combination with two NRTIs.
100 mg a Ritonavirkapsler, tabletter eller oral opløsning.
100 mg a Ritonavir capsules, tablets or oral solution.